These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2573707)

  • 1. Pharmacokinetics of cyanamide in dog and rat.
    Obach R; Colom H; Arso J; Peraire C; Pruñonosa J
    J Pharm Pharmacol; 1989 Sep; 41(9):624-7. PubMed ID: 2573707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of correlation between pharmacokinetic and pharmacodynamic behaviour of cyanamide in man. A preliminary report.
    Obach R; Pruñonosa J; Torrent J; Colom H; Peraire C; Izquierdo I; Domenech J
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():185-90. PubMed ID: 1820876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and oral bioavailability of carbimide in man.
    Obach R; Torrent J; Colom H; Pruñonosa J; Peraire C; Domenech J
    Biopharm Drug Dispos; 1991; 12(6):425-34. PubMed ID: 1932606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of cyanamide in fasted and unfasted rats.
    Obach R; Valenti C; Valles J; Valles JM; Domenech J
    Biopharm Drug Dispos; 1986; 7(3):273-80. PubMed ID: 3730527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absolute bioavailability and absorption profile of cyanamide in man.
    Colom H; Pruñonosa J; Peraire C; Domenech J; Azcona O; Torrent J; Obach R
    J Pharmacokinet Biopharm; 1999 Aug; 27(4):421-36. PubMed ID: 10826131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of cyanamide to cyanide and an inhibitor of aldehyde dehydrogenase (ALDH) by rat liver microsomes.
    Shirota FN; DeMaster EG; Kwon CH; Nagasawa HT
    Alcohol Alcohol Suppl; 1987; 1():219-23. PubMed ID: 3426683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of the oral triazole antimycotic vibunazole in animals.
    Ritter W; Plempel M
    J Antimicrob Chemother; 1984 Sep; 14(3):243-52. PubMed ID: 6490569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species.
    Monbaliu J; Verhaeghe T; Willems B; Bode W; Lavrijsen K; Meuldermans W
    Arzneimittelforschung; 2003; 53(7):486-95. PubMed ID: 12918214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of triflusal and its main metabolite in rats and dogs.
    Ramis J; Mis R; Forn J
    Eur J Drug Metab Pharmacokinet; 1991; 16(4):261-8. PubMed ID: 1823869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics and oral bioavailability studies of columbianetin in rats after oral and intravenous administration.
    Luo Q; Wang CP; Li J; Ma WF; Bai Y; Ma L; Gao XM; Zhang BL; Chang YX
    J Ethnopharmacol; 2013 Oct; 150(1):175-80. PubMed ID: 23994338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of pirtenidine in the rat and dog.
    Powles P; Usansky JI; Franklin RA
    Xenobiotica; 1989 Dec; 19(12):1349-54. PubMed ID: 2618086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.
    Jung D; Lin L; Jiao H; Cai X; Duan JX; Matteucci M
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):643-54. PubMed ID: 21964906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic profile of idazoxan in the beagle dog.
    Vallès J; Pruñonosa J; Menargues A; Nomen M; Obach R
    J Pharm Pharmacol; 1989 Jun; 41(6):384-7. PubMed ID: 2570833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of pidotimod in rats and dogs.
    Coppi G; Silingardi S
    Arzneimittelforschung; 1994 Dec; 44(12A):1460-4. PubMed ID: 7857342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration.
    Studenberg SD; Woolley JL; Deangelis DV; Wargin WA
    Biopharm Drug Dispos; 1997 Jul; 18(5):433-42. PubMed ID: 9210981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral idazoxan bioavailability in rat. Relevance of intestinal and hepatic first-pass effect.
    Vallès J; Pruñonosa J; Menargues A; Nomen M; Obach R
    Drug Metab Dispos; 1989; 17(6):673-6. PubMed ID: 2575506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of astragaloside iv in beagle dogs.
    Zhang Q; Zhu LL; Chen GG; Du Y
    Eur J Drug Metab Pharmacokinet; 2007; 32(2):75-9. PubMed ID: 17702194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of rat hepatic mitochondrial aldehyde dehydrogenase isozymes by repeated cyanamide administration: pharmacokinetic-pharmacodynamic relationships.
    Pruñonosa Piera J; Obach R; Sagristá ML; Bozal J
    Biopharm Drug Dispos; 1993 Jul; 14(5):419-28. PubMed ID: 8218960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary excretion of acetylcyanamide in rat and human after oral and dermal application of hydrogen cyanamide (H2NCN).
    Mertschenk B; Bornemann W; Filser JG; von Meyer L; Rust U; Schneider JC; Gloxhuber C
    Arch Toxicol; 1991; 65(4):268-72. PubMed ID: 1953345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.